PYC Therapeutics Limited

OTCPK:PYCX.F Stock Report

Market Cap: US$454.9m

PYC Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Rohan Hockings

Chief executive officer

AU$625.5k

Total compensation

CEO salary percentage63.15%
CEO tenure5.2yrs
CEO ownershipn/a
Management average tenure5.2yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rohan Hockings's remuneration changed compared to PYC Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025AU$625kAU$395k

-AU$50m

Mar 31 2025n/an/a

-AU$49m

Dec 31 2024n/an/a

-AU$48m

Sep 30 2024n/an/a

-AU$43m

Jun 30 2024AU$433kAU$395k

-AU$38m

Mar 31 2024n/an/a

-AU$30m

Dec 31 2023n/an/a

-AU$22m

Sep 30 2023n/an/a

-AU$22m

Jun 30 2023AU$438kAU$395k

-AU$23m

Mar 31 2023n/an/a

-AU$23m

Dec 31 2022n/an/a

-AU$24m

Sep 30 2022n/an/a

-AU$19m

Jun 30 2022AU$418kAU$395k

-AU$14m

Mar 31 2022n/an/a

-AU$15m

Dec 31 2021n/an/a

-AU$17m

Sep 30 2021n/an/a

-AU$17m

Jun 30 2021n/an/a

-AU$18m

Mar 31 2021n/an/a

-AU$15m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$9m

Jun 30 2020AU$471kAU$395k

-AU$7m

Mar 31 2020n/an/a

-AU$6m

Dec 31 2019n/an/a

-AU$5m

Sep 30 2019n/an/a

-AU$5m

Jun 30 2019AU$482kAU$395k

-AU$4m

Compensation vs Market: Rohan's total compensation ($USD406.55K) is below average for companies of similar size in the US market ($USD2.32M).

Compensation vs Earnings: Rohan's compensation has increased whilst the company is unprofitable.

CEO

Rohan Hockings (42 yo)

5.2yrs
Tenure
AU$625,478
Compensation

Dr. Rohan Hockings, MBBS (Hons.), J.D., G.D.L.P, has been Chief Executive Officer at PYC Therapeutics Limited since August 2020. He served as Chief Strategy Officer at PYC Therapeutics Limited until August...

Leadership Team

NamePositionTenureCompensationOwnership
Rohan Hockings
CEO & Executive Director5.2yrsAU$625.48kno data
Andrew Taylor
CFO & Company Secretary3.5yrsno datano data
Sri Mudumba
Chief Research & Development Officerno datano datano data
Paula Cunningham
Chief Pre-Clinical Research Officerno datano datano data
Kevin Hart
Company Secretary8.3yrsAU$165.90kno data
5.2yrs
Average Tenure

Experienced Management: PYCX.F's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rohan Hockings
CEO & Executive Director6.9yrsAU$625.48kno data
Alan Tribe
Non-Executive Chair of the Board7.5yrsAU$80.00k32.01%
$ 145.6m
Fred Chen
Member of Scientific Advisory Board & Member of Ophthalmology Clinical Advisory Board6.1yrsno datano data
Alexander Kolevzon
Member of Scientific Advisory Boardno datano datano data
Mark Pennesi
Member of Scientific Advisory Board4.2yrsno datano data
Aron Chakera
Member of Scientific Advisory Boardno datano datano data
Ian Constable
Member of Scientific Advisory Board & Directorless than a yearno data0.035%
$ 159.9k
Neera Dahl
Member of Scientific Advisory Boardno datano datano data
Peter Harris
Member of Scientific Advisory Boardno datano datano data
K Jayasundera
Member of Scientific Advisory Boardno datano datano data
Wai Yu
Member of Scientific Advisory Boardno datano datano data
6.1yrs
Average Tenure

Experienced Board: PYCX.F's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/18 04:18
End of Day Share Price 2025/08/13 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PYC Therapeutics Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
David MartinBloom Burton & Co.